Patents by Inventor Chul Hyun Yu

Chul Hyun Yu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted pyrazolo[4,3-d]pyrimidines as aurora kinase inhibitors
    Patent number: 7932257
    Abstract: The present invention provides compounds having the formula: wherein A-B together represent one of the following structures: wherein one of is a double bond, as valency permits; and R2, R4, X1A, X2A, X1B, X2B, L1, L2, Y and Z are as defined in classes and subclasses herein, and pharmaceutical compositions thereof, as described generally and in subclasses herein, which compounds are useful as inhibitors of protein kinase (e.g., Aurora), and thus are useful, for example, for the treatment of Aurora mediated diseases.
    Type: Grant
    Filed: July 21, 2006
    Date of Patent: April 26, 2011
    Assignee: Sunesis Pharmaceuticals, Inc.
    Inventors: Johan D. Oslob, Chul Hyun Yu
  • Small-molecule inhibitors of interleukin-2
    Patent number: 6806279
    Abstract: Compounds of formulae I and I′, methods of making them, pharmaceutical compositions containing them, and methods for their use. The compounds are antagonists of IL-2/IL-2R binding; and are useful for the treatment of interleukin-2 mediated diseases, such as autoimmune diseases (such as rheumatoid arthritis, multiple sclerosis, uveitis, and psoriasis), allograft rejection, and graft-versus-host disease.
    Type: Grant
    Filed: December 17, 2001
    Date of Patent: October 19, 2004
    Assignee: Sunesis Pharmaceuticals, Inc.
    Inventors: Michelle R. Arkin, Robert S. McDowell, Johan D. Oslob, Brian C. Raimundo, Nathan D. Waal, Chul Hyun Yu
  • Small-molecule inhibitors of interleukin-2
    Publication number: 20030149049
    Abstract: Compounds of formulae I and I′, methods of making them, pharmaceutical compositions containing them, and methods for their use. The compounds are antagonists of IL-2/IL-2R binding; and are useful for the treatment of interleukin-2 mediated diseases, such as autoimmune diseases (such as rheumatoid arthritis, multiple sclerosis, uveitis, and psoriasis), allograft rejection, and graft-versus-host disease.
    Type: Application
    Filed: December 17, 2001
    Publication date: August 7, 2003
    Inventors: Michelle R. Arkin, Robert S. McDowell, Johan D. Oslob, Brian C. Raimundo, Nathan D. Waal, Chul Hyun Yu